SCHEMBL5714945

SCHEMBL5714945

O=C(O)c1ccc(N2CCN(C(=O)Oc3ccc(Cc4ccc(C(F)(F)F)cc4)cc3)CC2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.54
HPGD P15428 1/20 0.54
TRPV1 Q8NER1 1/20 0.51
TRPA1 O75762 1/20 0.50
PRKAA2 P54646 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 2/20 0.48
ALDH1A1 P00352 2/20 0.48
LIPE Q05469 3/20 0.46
SRD5A2 P31213 1/20 0.46
SMO Q99835 1/20 0.46
MAPT P10636 2/20 0.45
BCHE P06276 1/20 0.45
IDE P14735 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715258 0.92 SMN1; SMN2 (0.55) SMN1; SMN2HPGDTRPV1PRKAA2MEN1
SCHEMBL5714721 0.91 SMN1; SMN2 (0.65) SMN1; SMN2HPGDTRPV1TRPA1MEN1
SCHEMBL5714889 0.88 SMN1; SMN2 (0.54) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5714947 0.88 SMN1; SMN2 (0.56) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5715657 0.87 TRPA1 (0.56) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5715468 0.87 SMN1; SMN2 (0.61) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5715572 0.85 LIPE (0.68) SMN1; SMN2HPGDMEN1KMT2ACYP1A2
SCHEMBL5714308 0.85 HIF1A (0.47) TRPV1TRPA1PRKAA2LIPESRD5A2
SCHEMBL5714727 0.84 SMN1; SMN2 (0.62) SMN1; SMN2HPGDTRPV1TRPA1MEN1
SCHEMBL5714086 0.83 TRPV1 (0.61) SMN1; SMN2HPGDTRPV1TRPA1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC SMN1; SMN2 2732/4885HPGD 793/4885TRPV1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.